Search hospitals
>
Ohio
>
Cincinnati
Cincinnati Children's Hospital Medical Center
Claim this profile
Cincinnati, Ohio 45229
Global Leader in Brain Tumor
Global Leader in Cancer
Conducts research for Solid Tumors
Conducts research for Neuroblastoma
Conducts research for Leukemia
1909 reported clinical trials
143 medical researchers
Summary
Cincinnati Children's Hospital Medical Center is a medical facility located in Cincinnati, Ohio. This center is recognized for care of Brain Tumor, Cancer, Solid Tumors, Neuroblastoma, Leukemia and other specialties. Cincinnati Children's Hospital Medical Center is involved with conducting 1,909 clinical trials across 1,886 conditions. There are 143 research doctors associated with this hospital, such as Brian Weiss, MD, Joseph G. Pressey, Erin H Breese, MD, PhD, and Peter de Blank, MD.
Area of expertise
Brain Tumor
Cincinnati Children's Hospital Medical Center has run 121 trials for Brain Tumor. Some of their research focus areas include:
Cancer
Cincinnati Children's Hospital Medical Center has run 115 trials for Cancer. Some of their research focus areas include:
Top PIs
Brian Weiss, MD
Cincinnati Children's Hospital Medical Center
5 years of reported clinical research
Joseph G. Pressey
Cincinnati Children's Hospital Medical Center
10 years of reported clinical research
Erin H Breese, MD, PhD
Cincinnati Children's Hospital Medical Center
8 years of reported clinical research
Peter de Blank, MD
Cincinnati Children's Hospital Medical Center
6 years of reported clinical research
Clinical Trials running at Cincinnati Children's Hospital Medical Center
Neuroblastoma
Brain Tumor
Testicular cancer
Cystic Fibrosis
Chronic Kidney Disease
Lazy Eye
Attention Deficit Hyperactivity Disorder (ADHD)
Attention-Deficit/Hyperactivity Disorder (ADHD)
Crohn's Disease
Ovarian Carcinoma
Dabrafenib + Trametinib
for Brain Tumors
This trial is studying the effects of two cancer medications, dabrafenib and trametinib, in children. These drugs work by stopping signals that make cancer cells grow. Dabrafenib and trametinib have shown benefits in various BRAF-mutant tumors, including melanoma, lung cancer, and thyroid cancer. The goal is to see how these treatments affect children over time.
Recruiting
3 awards
Phase 4
7 criteria
Dinutuximab + Chemotherapy
for High-Risk Neuroblastoma
This phase III trial tests how well the addition of dinutuximab to Induction chemotherapy along with standard of care surgical resection of the primary tumor, radiation, stem cell transplantation, and immunotherapy works for treating children with newly diagnosed high-risk neuroblastoma. Dinutuximab is a monoclonal antibody that binds to a molecule called GD2, which is found on the surface of neuroblastoma cells, but is not present on many healthy or normal cells in the body. When dinutuximab binds to the neuroblastoma cells, it helps signal the immune system to kill the tumor cells. This helps the cells of the immune system kill the cancer cells, this is a type of immunotherapy. When chemotherapy and immunotherapy are given together, during the same treatment cycle, it is called chemoimmunotherapy. This clinical trial randomly assigns patients to receive either standard chemotherapy and surgery or chemoimmunotherapy (chemotherapy plus dinutuximab) and surgery during Induction therapy. Chemotherapy drugs administered during Induction include, cyclophosphamide, topotecan, cisplatin, etoposide, vincristine, and doxorubicin. These drugs work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing or by stopping them from spreading. Upon completion of 5 cycles of Induction therapy, a disease evaluation is completed to determine how well the treatment worked. If the tumor responds to therapy, patients receive a tandem transplantation with stem cell rescue. If the tumor has little improvement or worsens, patients receive chemoimmunotherapy on Extended Induction. During Extended Induction, dinutuximab is given with irinotecan, temozolomide. Patients with a good response to therapy move on to Consolidation therapy, when very high doses of chemotherapy are given at two separate points to kill any remaining cancer cells. Following, transplant, radiation therapy is given to the site where the cancer originated (primary site) and to any other areas that are still active at the end of Induction. The final stage of therapy is Post-Consolidation. During Post-Consolidation, dinutuximab is given with isotretinoin, with the goal of maintaining the response achieved with the previous therapy. Adding dinutuximab to Induction chemotherapy along with standard of care surgical resection of the primary tumor, radiation, stem cell transplantation, and immunotherapy may be better at treating children with newly diagnosed high-risk neuroblastoma.
Recruiting
2 awards
Phase 3
7 criteria
Lorlatinib + Standard Therapy
for Neuroblastoma
This phase III trial studies iobenguane I-131 or lorlatinib and standard therapy in treating younger patients with newly-diagnosed high-risk neuroblastoma or ganglioneuroblastoma. Radioactive drugs, such as iobenguane I-131, may carry radiation directly to tumor cells and not harm normal cells. Lorlatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving iobenguane I-131 or lorlatinib and standard therapy may work better compared to lorlatinib and standard therapy alone in treating younger patients with neuroblastoma or ganglioneuroblastoma.
Recruiting
2 awards
Phase 3
22 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Cincinnati Children's Hospital Medical Center?
Cincinnati Children's Hospital Medical Center is a medical facility located in Cincinnati, Ohio. This center is recognized for care of Brain Tumor, Cancer, Solid Tumors, Neuroblastoma, Leukemia and other specialties. Cincinnati Children's Hospital Medical Center is involved with conducting 1,909 clinical trials across 1,886 conditions. There are 143 research doctors associated with this hospital, such as Brian Weiss, MD, Joseph G. Pressey, Erin H Breese, MD, PhD, and Peter de Blank, MD.
Where is Cincinnati Children's Hospital Medical Center located?
**Directions to Cincinnati Children's Hospital Medical Center:** - **Address:** 3333 Burnet Ave, Cincinnati, OH 45229. - **Directions:** Take I-71 S to exit 3A for Reading Rd. Turn left onto Reading Rd, which continues onto Burnet Ave. The hospital will be on your right.
Who should I call to ask about financial aid or insurance network?
**Cincinnati Children's Hospital Medical Center Financial and Insurance Assistance Contacts** - **Financial Assistance**: Email PFC@cchmc.org or call 513-803-6577, Monday – Friday, 7:30 a.m. to 5:00 p.m. - **Financial Advocates**: Contact at 513-636-4427 or email FFA@cchmc.org for financial resource assistance. - **Billing**: For billing inquiries, visit the Online Business Office or call 1-877-430-8495 option #1 or 513-636-4427. - **Insurance**: For insurance questions, call 513-636-4200 (local) or 1-800-344-2462 (toll free). - **Patient Financial Services**: Write to CCHMC Patient Financial Services, 3333 Burnet Avenue, MLC 5011, Cincinnati, OH 45229-3026 for additional financial assistance.
What insurance does Cincinnati Children's Hospital Medical Center accept?
Cincinnati Children's Hospital Medical Center accepts most insurance plans, including Medicaid, Molina, and Paramount. They offer resources for families with special healthcare needs and those under or uninsured, assisting with health insurance issues. For individual coverage details, it's advised to contact the insurance carrier directly.
What awards or recognition has Cincinnati Children's Hospital Medical Center received?
Cincinnati Children's Hospital Medical Center is renowned for its exceptional research and care, earning the #1 spot on the 2023-24 U.S. News & World Report list of Best Children's Hospitals. It also ranks second among all children's hospitals and medical school pediatric departments in terms of research funding from the National Institutes of Health (NIH).
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.